Uninhibited neurogenic bladder treated with Prazosin.
The effect of the new alpha-adrenoreceptor blocking agent prazosin on hypermotility of the urinary bladder was investigated, using controlled cystometry in neurological patients with normal bladder or with uninhibited neurogenic bladder. In short-term administration of prazosin, the bladder capacity was markedly increased and the uninhibited detrusor contraction was diminished. Long-term treatment with prazosin gave subjectively improved micturition in patients with detrusor-sphincter dyssynergia. The cystometrograms then showed less pronounced improvement than in short-term medication. Prazosin offers a valuable supplement to the existing choice off therapeutic agents for uninhibited neurogenic bladder. Side effects of the drug were few.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011224:Prazosin / Q000009:adverse effects / Q000627:therapeutic use*; D011312:Pressure; D011799:Quinazolines / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000187:drug effects; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*
D011799:Quinazolines; D011224:Prazosin